LABCORP HOLDINGS INC.
Public company- Headquarters
- BURLINGTON, North Carolina
- Ticker
- LH
- CIK
- 0000920148
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
| Notice date | Workers affected | Cumulative |
|---|---|---|
| Feb 2, 2024 | 239 | 239 |
| May 13, 2024 | 81 | 320 |
| Sep 16, 2024 | 53 | 373 |
| Mar 3, 2025 | 73 | 446 |
| Mar 17, 2026 | 60 | 506 |
| Jul 3, 2026 | 83 | 589 |
Leadership
| Role and person | Since | Change |
|---|---|---|
| Executive Vice President and President, Central Laboratories and InternationalMegan D. Bailey | Aug 14, 2026 | Departed |
| Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific OfficerBrian J. Caveney, M.D. | Aug 14, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- Fortrea Holdings Inc.
Chief Accounting Officer appointed: Carrie Russell
- Guardant Health, Inc.
Class II director appointed: Kevin R. Sayer
- QUEST DIAGNOSTICS INC
Executive Vice President role change: Catherine T. Doherty
- Celcuity Inc.
director appointed: David W. Gryska
- Executive departure
Executive Vice President and President, Central Laboratories and International departs: Megan D. Bailey
Megan D. Bailey, Executive Vice President and President, Central Laboratories and International of LABCORP HOLDINGS INC., resigns the role, effective September 4, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 14, 2026Role: Executive Vice President and President, Central Laboratories and International
- Executive appointment
Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer appointed: Brian J. Caveney, M.D.
Brian J. Caveney, M.D. was named Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer of LABCORP HOLDINGS INC., effective September 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 14, 2026Role: Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer
Last verified Nov 8, 2026